The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer. METHODS: We randomly assigned patients with completely resected stage IB or stage II non-small-cell lung cancer to vinorelbine plus cisplatin or to observation. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimen. RESULTS: A total of 482 patients underwent randomization to vinorelbine plus cisplatin (242 patients) or observation (240); 45 percent of the patients had pathological stage IB disease and 55 percent had stage II, and all had an Eastern Cooperative Oncology Group performance status score of 0 or 1. In both groups, the median age was 61 years, 65 percent were men, and 53 percent had adenocarcinomas. Chemotherapy caused neutropenia in 88 percent of patients (including grade 3 febrile neutropenia in 7 percent) and death from toxic effects in two patients (0.8 percent). Nonhematologic toxic effects of chemotherapy were fatigue (81 percent of patients), nausea (80 percent), anorexia (55 percent), vomiting (48 percent), neuropathy (48 percent), and constipation (47 percent), but severe (grade 3 or greater) toxic effects were uncommon (<10 percent). Overall survival was significantly prolonged in the chemotherapy group as compared with the observation group (94 vs. 73 months; hazard ratio for death, 0.69; P=0.04), as was relapse-free survival (not reached vs. 46.7 months; hazard ratio for recurrence, 0.60; P<0.001). Five-year survival rates were 69 percent and 54 percent, respectively (P=0.03). CONCLUSIONS: Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
Kelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Self-citationA Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Le Chevalier, T., Brisgand, D., Douillard, J. Y., Pujol, J. L., Alberola, V, Monnier, A., Riviere, A., Lianes, P., Chomy, P., & Cigolari, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.360 · Cited by 811
Scagliotti, G. V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg059 · Cited by 593
Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., & Johnson, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.623 · Cited by 589
Self-citationKeller, S. M., Adak, S., Wagner, H., Herskovic, A., Komaki, R., Brooks, B. J., Perry, M. C., Livingston, R. B., & Johnson, D. H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010263431703 · Cited by 446
Self-citationBunn, P. A., & Kelly, K. L. (1998) · PubMed · Cited by 400
WALLER, D., PEAKE, M., STEPHENS, R., GOWER, N., MILROY, R., PARMAR, M., RUDD, R., SPIRO, S., & ONBEHALFOFALLBLTPARTICIPANTS (2004) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2004.03.041 · Cited by 387
Strauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., & Green, M. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7019 · Cited by 380
Giaccone, G., Splinter, T. A., Debruyne, C., Kho, G. S., Lianes, P., van Zandwijk, N., Pennucci, M. C., Scagliotti, G., van Meerbeeck, J., van Hoesel, Q., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2133 · Cited by 275
Mitsudomi, T., Steinberg, S. M., Oie, H. K., Mulshine, J. L., Phelps, R. M., Viallet, J., Pass, H. I., Minna, J. D., & Gazdar, A. F. (1991) · PubMed · Cited by 248
Exact Confidence Intervals Following a Group Sequential Test
Tsiatis, A. A., Rosner, G. L., & Mehta, C. R. (1984) · Biometrics · doi:10.2307/2530924 · Cited by 224
Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer*
Socinski, M. A., Morris, D. E., Masters, G. A., & Lilenbaum, R. (2003) · Chest · doi:10.1378/chest.123.1_suppl.226s · Cited by 203
Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients
Mate, J. L. (1994) · Lung Cancer · doi:10.1016/0169-5002(94)90325-5 · Cited by 156
Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer
Alam, N. Z., Shepherd, F. A., Winton, T. L., Graham, B., Johnson, D. H., Livingston, R. B., Rigas, J. R., Whitehead, M., Ding, K., & Seymour, L. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.08.016 · Cited by 134
Self-citationTsao, M., Liu, G., Nicklee, T., Shepherd, F. A., & Viallet, J. (1997) · PubMed · Cited by 47
Self-citationIs cisplatin still the best platinum compound in non-small-cell lung cancer?
Soria, J., & Chevalier, T. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf331 · Cited by 23
Lung cancer * 4: Chemotherapy for non-small cell lung cancer: the end of the beginning
Cullen, M. H. (2003) · Thorax · doi:10.1136/thorax.58.4.352 · Cited by 21
Zojwalla, N. J., Raftopoulos, H., & Gralla, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7068 · Cited by 21
Cited by
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60735-0 · Cited by 3,908
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citationPostmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727
Metadata
- Authors
- Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., Fry, W., Bethune, D., Ayoub, J., Ding, K., Seymour, L., Graham, B., Tsao, M.-S., Gandara, D., Kesler, K., Demmy, T., & Shepherd, F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-23
- Volume
- 352
- Issue
- 25
- Pages
- 2589-2597
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127342594
- Cited by
- 1,810
- References
- 29
- FWCI
- 105.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.